The Risks of Incident and Recurrent Clostridium difficile-Associated Diarrhea in Chronic Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis

Digestive Diseases and Sciences

Volumn 60, Issue 10, 2015, Pages 2913-2922

  Phatharacharukul, Parkpoom ^a   Thongprayoon, Charat ^b   Cheungpasitporn, Wisit ^b   Edmonds, Peter J ^c   Mahaparn, Pailin ^d   Bruminhent, Jackrapong ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

C. diff infection; C. difficile; Chronic kidney disease; Clostridium difficile; Clostridium difficile associated colitis; Dialysis; Diarrhea; End stage kidney disease; Infection; Infectious disease; Meta analysis

Indexed keywords

CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DIARRHEA; END STAGE RENAL DISEASE; HAZARD RATIO; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; COMORBIDITY; DRUG COMBINATION; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FOLLOW UP; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; COMORBIDITY; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 84942191136     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3714-9     Document Type: Review

References (37)

1. Depestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26:464–475.
2. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531–534.
3. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol. 2006;44:2785–2791.
4. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–834.
5. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272.
6. Cheungpasitporn W, Thongprayoon C, O’Corragain OA, Edmonds PJ, Kittanamongkolchai W, Erickson SB. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton). 2014;19:791–797.
7. Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87:1046–1053.
8. Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Mahaparn P, Bruminhent J. High mortality risk in chronic kidney disease and end stage kidney disease patients with Clostridium difficile infection: a systematic review and meta-analysis. J Nat Sci. 2015;1:e85.
9. Wei HL, Wei SH, Huang CW, et al. Molecular typing and epidemiology of Clostridium difficile in respiratory care wards of central Taiwan. J Microbiol Immunol Infect. 2015;48:65–71.
10. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103:2308–2313.
11. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954–959.
12. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33–38.
13. Keshavamurthy S, Koch CG, Fraser TG, et al. Clostridium difficile infection after cardiac surgery: prevalence, morbidity, mortality, and resource utilization. J Thorac Cardiovasc Surg. 2014;148:e3151–e3155.
14. Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38:1–11.
15. Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70:142–147.
16. Buchner AM, Sonnenberg A. Medical diagnoses and procedures associated with Clostridium difficile colitis. Am J Gastroenterol. 2001;96:766–772.
17. Allen C, O’Shea T, Zarowitz BJ, Strauss ME. The burden of C. difficile infection (CDI) in nursing home (NH) residents. In: Journal of the American Geriatrics Society conference: 2014 annual scientific meeting of the American Geriatrics Society Orlando, FL, United States; S38.
18. Lai CC, Lin SH, Tan CK, Liao CH, Huang YT, Hsueh PR. Clinical manifestations of Clostridium difficile infection in a medical center in Taiwan. J Microbiol Immunol Infect. 2014;47:491–496.
19. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol. 2012;46:397–400.
20. D’Agata EM, Mount DB, Thayer V, Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis. 2000;35:1083–1088.
21. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63–73.
22. Samie AA, Traub M, Bachmann K, Kopischke K, Theilmann L. Risk factors for recurrence of Clostridium difficile-associated diarrhoea. Hepato-gastroenterology. 2013;60:1351–1354.
23. Huang H, Wu S, Chen R, et al. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe. 2014;30:65–69.
24. Ewelukwa O, Cheema B, Metzger S, Markert RJ, Akram S. Socioeconomic differences in the risk of developing Clostridium difficile diarrhea: a case-control study. In: Gastroenterology conference: digestive disease week 2014, DDW 2014 Chicago, IL, United States; S254–S255.
25. Yousuf K, Saklayen MG, Markert RJ, Barde CJ, Gopalswamy N. Clostridium difficile-associated diarrhea and chronic renal insufficiency. South Med J. 2002;95:681–683.
26. Eddi R, Malik MN, Shakov R, Baddoura WJ, Chandran C, Debari VA. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton). 2010;15:471–475.
27. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
28. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
29. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
31. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–872.
32. Kim HK, Kim SC, Kim MG, Jo SK, Cho WY. Advanced chronic kidney disease is a strong risk factor for Clostridium difficile infection. In: Nephrology dialysis transplantation conference: 51st ERA-EDTA congress Amsterdam, Netherlands; 2014: iii414.
33. Leung AC, Orange G, McLay A, Henderson IS. Clostridium difficile-associated colitis in uremic patients. Clin Nephrol. 1985;24:242–248.
34. Aronsson B, Barany P, Nord CE, Nystrom B, Stenvinkel P. Clostridium difficile-associated diarrhoea in uremic patients. Eur J Clin Microbiol. 1987;6:352–356.
35. Herrera P, Cotera A, Fica A, Galdo T, Alvo M. High incidence and complications of Clostridium difficile diarrhea among patients with renal diseases. Rev Med Chile. 2003;131:397–403.
36. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013;9:255–265.
37. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:403–410.